Oncology

How community oncology practices are expanding access to innovative therapies while navigating reimbursement and care delivery challenges.

Lifileucel treats advanced melanoma by harvesting, expanding, and reinfusing a patient's own tumor-infiltrating immune cells.

Tracking PDUFA decisions and early planning can lead to safe, rapid access to new medications for patients.

Pharmacy Times interviews Robert R. Jeng, MD, on how the gut microbiome may influence CAR T-cell therapy response, toxicity, and persistence, as well as the challenges and future potential of microbiome-based interventions in improving patient outcomes.

Pharmacy Times interviews Kamel Lahouel, PhD, and Cristian Tomasetti, PhD, on the challenges of predicting MHC class II peptide binding and how combining structural and sequence-based models can improve accuracy while addressing key limitations.

AACR data show tumor molecular profiling finds actionable PIK3CA in breast and colorectal cancer, while ctDNA adds real-time monitoring in oncology.

Pharmacists play a crucial role in evaluating 505(b)(2) drugs—from ensuring oncology therapeutic equivalence to improving access and outcomes.

Pharmacy Times interviewed Kimlin Ashing and Narissa Nonzee about their work examining how housing status, race, and ethnicity drive cancer screening disparities.

Research presented at the American Association for Cancer Research Annual Meeting shows personalized mRNA vaccine immunotherapy targets pancreatic cancer tumor neoantigens, sparking durable T-cell responses and boosting survival in a phase 1 clinical trial.

Oncology teams can address AI-driven cancer cures with empathy, evidence, and safer next steps to protect patients and trust.

EPCORE trial data show epcoritamab plus lenalidomide and rituximab delivers responses in relapsed/refractory follicular lymphoma with outpatient dosing.

Amber Clemmons PharmD, BCOP, FHOPA, highlights key changes in evidence grading, shared decision-making, and dosing strategies in neutropenia management.

Gwen Nichols shares her dream of changing the landscape of pediatric cancer research and care.

Cone Health Cancer Center pharmacists lead bispecific T-cell engager rollout, boosting local access to care.

Adjuvant PD-1/PD-L1 inhibitors improve disease-free and metastasis-free survival in patients with solid tumors but require careful patient selection.

Pharmacist lung cancer insights on NSCLC: biomarker testing, PD-1 choices like cemiplimab, and access tips for treating non small cell lung cancer.

COVID-19 infection may create lasting changes in the lung microenvironment—particularly through thymidine phosphorylase–driven pathways—that could increase the risk of lung cancer over time.

WHI data link radon exposure to higher ovarian cancer risk and deaths; learn how home testing may reduce cancer risk in high-radon areas.

Emerging therapeutic options represent a new age for treatment of high-risk non–muscle invasive bladder cancer.

FDA fast track designation advances oral EP300/CBP inhibitor OPN-6602 for relapsed/refractory multiple myeloma, highlighting novel hematology-oncology options and key pharmacist considerations.

Students should consider reaching out to their experiential education department to learn what opportunities may be available.

Cristian Tomasetti, PhD, explains how obesity enlarges organs, raising cancer risk, and how GLP-1 weight loss therapy may reverse this, guiding oncology pharmacists.

In AML, sialylated CD43 blocks immune clearance beyond CD47, revealing new leukemia targets to boost macrophage phagocytosis.

TIL therapy offers a new metastatic melanoma option while FDA PDUFA dates reshape oncology approvals and planning.

This is the second complete response letter the manufacturer has received for this treatment regimen.